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Physiological	change	at	the	end	of	life	in	heart	failure	
Change	in	physiological	variables	in	the	last	2	weeks	of	life:		An	
observational	study	of	hospitalized	adults	with	heart	failure.	
	
Abstract	
	
Context:	Recognition	of	dying	is	a	difficult	task	in	end-stage	heart	failure,	yet	it	remains	
an	important	clinical	skill	in	providing	good	palliative	care	to	these	patients.	
	
Objectives:		To	use	routinely	collected	data	to	explore	evidence	for	physiological	
change	in	the	final	two	weeks	of	life	in	end-stage	heart	failure.	
	
Methods:	This	was	a	retrospective	cohort	study	of	routinely	collected	data	from	
hospital	in-patients	dying	as	a	result	of	heart	failure	during	a	1-year	period	in	a	UK	
hospital.		Data	were	analyzed	using	descriptive	techniques	and	multilevel	modelling.	
	
Results:	Results	were	obtained	on	81	patients.		Respiratory	function	(evidenced	by	
falling	oxygen	saturation	and	rising	respiratory	rate)	deteriorated	by	a	clinically	
significant	amount	in	the	final	two	weeks	of	life	(p<0.001).		Renal	function	(evidenced	
by	rising	serum	urea	and	creatinine)	also	demonstrated	a	clinically	significant	
deterioration	over	the	same	time	period	(p<0.001	and	p=0.005	respectively).		Serum	
albumin	fell	over	a	period	of	months	(p<0.001).		Heart	rate	and	blood	pressure	did	not	
demonstrate	clinically	significant	change	over	the	same	time	period.	
	
Conclusions:	Deteriorating	respiratory	and	renal	function	may	indicate	imminent	
dying	in	heart	failure.		A	fall	in	serum	albumin	may	signify	poor	prognosis	over	a	
timescale	of	weeks	to	months.		Conversely,	hemodynamic	parameters	may	remain	
relatively	stable	in	the	final	days	of	life,	and	should	not	be	reassuring	in	end-stage	heart	
failure	patients.			
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Introduction.	
	
Management	of	heart	failure	has,	for	many	years,	focused	on	treatments	and	
interventions	designed	to	extend	prognosis,	limit	disease	progression	and	improve	
physical	symptoms	(1).		Whilst	these	aims	have	dominated	research	and	clinical	
practice,	the	progressive	and	ultimately	life-threatening	nature	of	the	condition	have	
created	a	remit	for	palliative	care	services	to	support	heart	failure	patients	(2);	a	recent	
US-based	RCT	demonstrated	clear	benefit	from	such	involvement	(3).			As	part	of	good	
palliative	care,	the	accurate	recognition	of	dying	is	an	important	clinical	skill,	allowing	
physicians	to	focus	on	symptom	relief	and	minimizing	unnecessary	medical	
interventions(4).	
	
Unfortunately,	whilst	recognition	of	dying	is	important	to	good	care,	the	task	remains	
challenging	(5).		The	unpredictable	trajectory	of	end-stage	heart	failure,	typified	by	
repeated	acute	hospital	admissions	on	a	background	of	inexorable	deterioration,	means	
that	anticipating	the	final	days	of	a	patient’s	life	is	a	complex	task	(6).		Whilst	various	
prognostic	tools	help	to	predict	survival	in	heart	failure	populations	at	a	longer	time	
scale(7),	existing	models	are	much	less	suited	to	translating	to	the	individual	patient	or	
to	the	timescale	of	days.	
	
When	developing	tools	to	support	prognostic	decision-making,	objectively	measurable	
clinical	parameters	are	valuable	sources	of	information	(8).		There	is	evidence,	however,	
that	dynamic	data,	incorporating	rate-of-change	information,	may	provide	further	
insight	into	end-of-life	change	in	palliative	conditions(9).		By	understanding	those	
changes	which	occur	in	the	final	days	to	weeks	of	life,	it	may	therefore	be	possible	to	
improve	recognition	of	dying	in	heart	failure	patients,	both	in	supporting	research	into	
new	predictive	models	and	in	clinical	application	at	the	patient	level.	
	
This	study	used	routinely	collected	clinical	data	to	explore	evidence	for	objective	
physiological	change	in	the	final	two	weeks	of	life,	with	a	view	to	improving	the	ability	
of	clinical	professionals	to	recognize	dying.			It	is	part	of	a	larger	mixed-methods	study	
which	includes	similar	data	from	cancer	patients.		Cancer	data	have	been	published	
elsewhere	(10).	
	
Method	
	
This	was	a	retrospective	observational	cohort	study,	using	longitudinal	modelling	of	
routinely	collected	clinical	data.	
	
A	review	of	prognostic	literature	identified	a	number	of	variables	which	were	suitable	
for	inclusion	in	the	study,	according	to	the	following	criteria:		1)	Associated	with	poor	
survival	in	end-stage	heart	failure,	2)	Routinely	recorded	in	medical	records,	3)	Ability	
to	exhibit	change	in	the	final	two	weeks	of	life,	4)	Could	be	measured	in	advanced	heart	
failure.		The	included	variables	are	listed	in	table	1.		Since	this	research	was	completed,	
the	European	Society	of	Cardiology	have	published	updated	information	of	prognostic	
factors	in	heart	failure(2),	consistent	with	those	included	in	the	study.	
	
The	study	was	conducted	at	a	National	Health	Service	(NHS)	hospital	in	the	UK	with	a	
specialist	cardiology	service.		Cases	were	identified	from	computer	coding	records	for	
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deaths	between	August	2009	and	July	2010	inclusive.		Adults	(>18)	in	which	the	
medical	certificate	of	cause	of	death	(MCCD)	listed	heart	failure	as	a	cause	or	
contributing	factor	were	included.		Synonyms	and	abbreviations	in	common	use	in	the	
UK	were	also	included	(cardiac	failure,	congestive	cardiac	failure,	left/right	ventricular	
failure,	systolic/diastolic	heart	failure).	
	
Cases	were	excluded	for	the	following	reasons:		Where	coroner’s	investigations	or	
litigation	were	in	place,	as	the	notes	would	need	to	be	rapidly	accessible	via	medical	
records	in	such	cases.			Where	deaths	occurred	in	intensive	care	or	high	dependency	
settings,	as	this	would	introduce	a	subset	of	patients	experiencing	significantly	different	
management	approaches	to	the	wider	group.			Where	there	were	insufficient	data	in	the	
notes	to	allow	analysis	(if,	for	example,	time	of	death	was	not	recorded).			
	
Identified	notes	were	screened	by	one	researcher	(PT)	for	evidence	of	clinical	heart	
failure	during	the	final	admission,	judged	by	medical	case-notes	and	use	of	drugs	to	
treat	the	condition.		If	no	evidence	was	found	for	active	heart	failure	in	the	final	
admission,	the	notes	were	to	be	excluded,	although	no	cases	were	excluded	on	this	basis	
alone.	
	
Data	were	extracted	from	the	medical	records	from	the	two	weeks	preceding	death;	
extended	to	three	months	for	hemoglobin	and	albumin	levels.		Data	were	anonymized	at	
source	and	entered	into	a	secure	bespoke	database	according	to	study	number.		
Variable	values	were	recorded	against	time	(for	observations)	or	date	(for	blood	tests).	
	
Multilevel	modelling	was	used	to	analyze	the	data.		This	is	a	longitudinal	analysis	
technique	suited	to	datasets	where	individual	data	sources	contribute	multiple	data	
points.		The	technique	involves	performing	a	regression	analysis	on	each	“level”	of	data.		
In	this	study,	the	first	level	of	data	was	the	individual;	an	association	between	value	and	
time	prior	to	death	was	generated	for	each	participant.		The	next	level	involved	collating	
these	individual	sets	to	generate	both	an	association	between	variable	value	and	time	
prior	to	death,	together	with	a	measure	of	variation	between	individual	trajectories.		
Analyses	were	performed	in	Stata	Version	11.0(Statacorp)	(11).		The	study	size	was	
determined	by	the	duration	of	the	study	(one	year).		
	
The	retrospective	data	collection	technique	meant	that	each	participant	contributed	an	
unpredictable	series	of	measures	and	there	was	scope	for	missing	or	censored	data.		
Some	would	have	had	only	a	small	number	of	results	recorded	before	a	clinical	decision	
to	discontinue	recording	was	undertaken.		Others	would	have	contributed	large	and	
detailed	data	sets;	this	has	the	potential	to	introduce	a	degree	of	selection	bias.			
	
Whilst	the	use	of	multilevel	modelling	was	intended	as	a	strategy	to	attenuate	the	risk	of	
selection	bias,	the	presence	and	impact	of	potential	bias	was	assessed	by	undertaking	
the	analysis	twice.		In	the	first	instance	the	complete	dataset	was	used,	including	those	
participants	with	large	amounts	of	missing	or	censored	data.		In	the	second,	the	analysis	
was	restricted	to	those	participants	who	had	detailed	data	sets.		Participant	data	was	
included	in	the	restricted	data	set	if	values	were	recorded	in	the	last	day	of	life	(or	final	
week	of	life	for	hemoglobin	and	albumin),	and	at	least	10	values	were	included.			
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Where	both	datasets	(“full”	and	“restricted”)	could	be	generated,	the	analysis	was	
performed	on	both.		Any	evidence	of	significant	variation	between	the	full	and	
restricted	datasets	would	be	evidence	of	bias	due	to	the	selection	method.	
	
The	study	is	reported	according	to	the	“Strengthening	the	Reporting	of	Observational	
Studies”	(STROBE)	guidelines(12).	
	
	
Results	
	
The	coding	search	identified	151	potential	records,	of	which	131	sets	of	notes	were	
available.		MCCD	criteria	were	met	in	99	cases.		Of	these	cases,	18	were	excluded	(6	
coroner’s	cases/litigation,	7	HDU/ICU,	7	insufficient	data,	some	duplicated).		This	
process	resulted	in	81	eligible	records.		Of	these	cases,	35	(43%)	were	male	and	46	
(57%	were	female).		Number	in	each	age	range	were:		61-70:	1;	71-80:16;	81-90:	51;	
91-100:	13.			
	
The	number	of	data	points	collected	for	each	variable,	together	with	descriptive	data,	
and	the	multilevel	models	are	presented	in	table	1.	
	
The	results	of	the	multilevel	models	are	summarized	in	Table	2.		These	provide	a	
description	of	the	change	in	values	of	the	parameters	over	time	in	the	final	two	weeks	of	
life.		The	intercept	is	the	projected	value	at	time	zero	(the	time	of	death).		This	acts	as	an	
anchor	point	for	the	changing	parameter	and	gives	an	indication	of	types	of	values	seen.		
It	is	useful	for	understanding	whether	the	results	are	clinically	significant.		The	co-
efficient	demonstrates	the	rate	of	change	over	time	prior	to	death.		A	variable	
decreasing	as	death	approaches	would	therefore	have	a	positive	co-efficient.	
	
Respiratory	rate,	serum	urea,	and	serum	creatinine	show	a	statistically	and	clinically	
significant	increase	in	the	final	two	weeks	of	life.		Oxygen	saturation	(as	measured	with	
an	infra-red	probe)	demonstrates	a	statistically	and	clinically	significant	decrease	in	the	
final	two	weeks	of	life.		Albumin	also	demonstrates	a	statistically	and	clinically	
significant	decrease,	measured	over	a	timescale	of	three	months.			
	
Heart	rate	and	serum	sodium	demonstrate	a	statistically	significant	increase,	but	their	
intercept	values	remain	within	the	normal	range	and	so	clinical	significance	is	limited.		
Blood	pressure,	serum	potassium	and	hematological	parameters	demonstrate	neither	
clinically	or	statistically	significant	change.	
	
For	parameters	where	sufficient	data	existed	to	provide	a	full	and	restricted	data	set,	
there	was	no	evidence	of	significant	difference	between	the	two.		Although	this	method	
does	not	provide	a	quantitative	assessment	of	the	risk	of	bias,	it	adds	a	degree	of	
reassurance	that	the	censored	data	has	not	had	a	major	effect	on	the	interpretation.	
	
	
	
	
Discussion		
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These	findings	demonstrate	that	physiological	change	in	the	final	two	weeks	of	life	in	
heart	failure	is	characterised	by	progressive	respiratory	and	renal	dysfunction,	but	with	
comparatively	stable	haemodynamic	parameters.		These	findings	may	be	compared	
with	the	results	of	the	earlier	cancer	study	(10),	which	demonstrated	similar	
respiratory	dysfunction	as	death	approached.		Renal	dysfunction	was	also	noted	in	
cancer,	but	the	derangement	in	renal	function	was	more	pronounced	in	heart	failure.			
	
Falling	albumin	is	also	associated	with	approaching	death,	but	these	results	were	
assessed	over	a	longer	time	period.		Cardiac	cachexia,	a	cause	of	hypoalbuminaemia	in	
this	population,	is	well	documented(13),	but	the	degree	and	rate	of	decline	of	albumin	
level	was	less	extreme	than	that	seen	in	cancer.	
	
Of	particular	interest,	and	potential	for	further	study,	is	the	relative	normality	of	certain	
parameters,	including	heart	rate,	blood	pressure	and	serum	sodium/potassium.		Given	
the	extensive	use	of	beta-blockers	in	this	population	(2),	it	may	be	expected	that	heart	
rate	would	not	increase	significantly	above	normal	levels.		The	relative	stability	of	blood	
pressure	in	end-stage	heart	failure	is,	however,	counter-intuitive,	given	a	progressive	
mechanical	pump	failure	and	hypotensive	side-effects	of	commonly	used	drugs	(Ace-
inhibitors,	Beta-blockers,	diuretics)	(2).		The	relative	normality	of	serum	sodium	and	
potassium	levels	is	similarly	counter-intuitive.		The	aforementioned	drugs,	in	
combination	with	a	context	of	renal	dysfunction	and	the	likely	increased	levels	of	
endogenous	natriuretic	peptides	(14),	mean	the	relative	normality	of	these	parameters	
is	unexpected.		Furthermore,	these	observations	are	at	odds	with	existing	prognostic	
studies	(2)		which	show	these	parameters	have	prognostic	value	at	longer	time	scales.			
	
This	study,	however,	considers	a	much	shorter	time	scale	than	existing	prognostic	
research	in	heart	failure,	which	may	help	explain	this	observation.		Reverse	
epidemiology,	a	phenomenon	which	has	been	observed	in	heart	failure	(15),	is	one	
potential	cause;	this	occurs	where	a	known	marker	of	poor	prognosis	is	unexpectedly	
associated	with	better	prognosis	in	certain	subgroups,	including	when	applied	to	
different	timescales.		It	is	also	possible	that	the	final	days	of	life	in	end-stage	heart	
failure	involve	refractory	responses	to	drugs,	an	observation	which	may	be	missed	over	
the	longer	time-scales	seen	in	prior	prognostic	studies.			
	
Whilst	anaemia	of	chronic	disease	is	an	observed	phenomenon	and	predictor	of	poor	
prognosis	in	heart	failure	(16),	and	the	study	results	show	values	at	the	lower	end	of	the	
normal	range,	these	findings	do	not	support	the	presence	of	progressive	anaemia	as	a	
predictor	of	poor	prognosis	at	the	short	time-scales	in	this	study.		These	findings	do	not	
preclude	the	potential	for	anaemia	to	have	prognostic	value	over	longer	time	scales.	
	
Death	from	heart	failure	may	therefore	be	understood	as	a	multi-organ	condition,	with	
evidence	of	systemic	cachectic	effects	over	a	longer	time	scale,	and	more	rapid	objective	
deterioration	over	the	final	days	to	weeks	of	life.			
	
The	observations	highlighted	warrant	further	study	using	prospective	methods.		In	
particular,	we	suggest	that	such	studies	collect	sequential	data	where	possible,	that	
analysis	techniques	allow	for	strengths	of	association	to	be	proposed,	and	that	
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additional	clinical	data	on	presenting	symptoms,	recognition	of	end-of-life	and	drug	use	
be	included.	
	
	
Limitations	
	
This	is	a	study	conducted	in	hospitalized	patients	outwith	the	HDU/ICU	setting	and,	as	a	
result,	cannot	necessarily	be	applied	to	other	patient	groups.		Furthermore,	the	need	to	
account	for	censored	data	highlights	that	there	was	variation	in	monitoring	strategies	
within	the	patient	group;	this	population	included	both	those	who	were	recognized	as	
dying	and	those	who	were	being	actively	treated,	so	cannot	be	applied	uncritically	to	
either	population.	
	
Legal	stipulations	on	death	certification	in	the	UK	do	not	permit	the	term	“Heart	
Failure”	alone	as	a	primary	cause	of	death,	unless	supported	with	a	preceding	qualifying	
condition.	It	is	possible,	therefore,	that	deaths	in	some	cases	with	clinical	heart	failure	
were	attributed	to	the	primary	cause	and	hence	were	not	included	in	the	sample.	
	
The	nature	of	this	study	method	precluded	the	inclusion	of	a	comparator	group,	and	
therefore	no	strength	of	association	can	be	provided	for	the	physiological	changes	
observed	here	and	the	risk	of	death	in	a	given	time	period.		Instead	these	results	are	
presented	as	the	basis	of	future	studies	using	prospective	methodology,	and	for	further	
understanding	of	the	physiological	changes	in	end-stage	heart	failure;	findings	from	the	
related	cancer	study	have	been	used	for	this	purpose	(17).	
	
The	proportion	of	deaths	occurring	due	to	heart	failure	by	gender	does	not	fully	reflect	
the	population	burden	of	cardiovascular	disease,	in	that	women	are	over-represented	
(57%).		However,	statistics	from	the	Office	for	National	Statistics,	which	presents	
aggregated	data	on	causes	of	death	in	the	UK,	highlights	that	heart	failure	as	the	cause	of	
death	is	more	common	in	women	(18).		Furthermore,	whilst	deaths	from	ischaemic	
heart	disease	are	over-represented	in	men(18),	other	causes	of	heart	failure	are	over-
represented	in	women(19),	with	associated	variation	in	mortality.		This	observation	
may	therefore	represent	a	genuine	gender	difference	in	recorded	mortality	rates	from	
heart	failure	in	hospital.	
	
Conclusions	
	
Respiratory	and	renal	dysfunction	are	potentially	useful	markers	for	approaching	death	
in	heart	failure,	especially	if	measured	values	are	abnormal	and	deteriorating.		Falling	
albumin	is	consistent	with	poor	prognosis	over	a	longer	time	period.	These	findings	are	
useful	for	understanding	the	biology	of	dying	as	a	result	of	heart	failure,	for	hypothesis	
generation,	and	for	describing	common	change	in	the	population	of	interest.			
	
In	terms	of	clinical	application,	the	relative	stability	and/or	normality	of	heart	rate,	
blood	pressure,	sodium,	potassium	and	haematological	parameters	in	this	data	set	
indicate	that	a	clinician	should	not	necessarily	be	reassured	if	these	values	are	stable	in	
an	otherwise	deteriorating	patient.	
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Physiological	change	at	the	end	of	life	in	heart	failure	
Table	1.		Variables	collected	and	descriptive	statistics.			
	
Variable	 Descriptive	statistics	
	 Number	of	values	(Patients)	 Lower	range	 Median	 Upper	range	
Heart	rate	(BPM)	
	
2332	(79)! 24! 84! 180!
Systolic	blood	pressure	(mmHg)	 2433	(79)! 44! 118! 237!
Diastolic	blood	pressure	(mmHg)	 2433	(79)! 16! 63! 141!
Respiratory	rate	(breaths/min)	 2299	(79)! 6! 20! 47!
Oxygen	saturation	(%)	 2401(79)! 60! 95! 100!
White	cells	(x	10
9
/L)
	
	
266	(79)! 3! 9.15! 37.1!
Lymphocytes	(x	10
9
/L)
	
264	(78)! 0.16! 0.8! 3.85!
Sodium	(mmol/L)	
	
326	(80)! 119! 137! 157!
Potassium	(mmol/L)	
	
311	(78)! 1.9! 4.4! 7!
Urea	(mmol/L)	
	
324	(79)! 2.7! 19.2! 63!
Creatinine		(µmol/L)	
				
325	(79)! 19! 172! 901!
Albumin	(g/L)	
	
767	(81)! 15! 30! 43!
Haemoglobin	(g/L)	
	
636	(81)! 5.6! 10.7! 17.3!
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Physiological	change	at	the	end	of	life	in	heart	failure	
Table	2.		Multilevel	modelling.		Co-efficients	represent	value	change	per	hour	for	bedside	
variables,	and	change	per	day	for	blood	results.	
	
Variable	 Multilevel	model	
	 Intercept	(95%	CI)	 Co-efficient	(95%	CI)	 Model	p-value		
Heart	rate	(BPM)	
Full	data	set	
86.7		
(83.2,	90.2)	
-0.022		
(-0.042,	-0.001)	
0.034	
Heart	rate	(BPM)	
Restricted	data	set	
87.7	(83.8,	91.6)	 -0-026	(-0-050,	-0-002)	 0.036	
Systolic	blood	pressure	(mmHg)	
Full	data	set	
119.5		
(114.4,	124.6)	
0.000		
(-0.032,	0.032)	
0.991	
Systolic	blood	pressure	(mmHg)	
Restricted	data	set	
121.9	(116.2,	127.6)	 -0-001	(-0-041,	0.040)	 0.978	
Diastolic	blood	pressure	(mmHg)	
Full	data	set	
64.4		
(61.3,	67.5)	
0.000		
(-0.014,	0.014)	
0.971	
Diastolic	blood	pressure	(mmHg)	
Restricted	data	set	
66.1	(62.6,	69.7)	 -0-004	(-0.020,	0.013)	 0.672	
Respiratory	rate	(breaths/min)	
Full	data	set	
22.9		
(21.8,	23.9)	
-0.012		
(-.0.18,	-0.005)	
<0.001	
Respiratory	rate	(breaths/min)	
Restricted	data	set	
23.3	((22.1,	24.4)	 -0.016	(-0-024,	-0.009)	 <0.001	
Oxygen	saturation	(%)	
Full	data	set	
93.0		
(92.3,	93.7)	
0.008		
(0.004,	0.011)	
<0.001	
Oxygen	saturation	(%)	
Restricted	data	set	
93.0	(92.2,	93.8)	 0.007	(.004,	0.011)	 <0.001	
Albumin	(g/L)	
Full	data	set	
27.3		
(26.20,	28.31)	
0.082		
(0.060,	0.105)	
<0.001	
Albumin	(g/L)	
Restricted	data	set	
25.6	(23.9,	27.3)	 0.114	(0.074,	0.154)	 <0.001	
Haemoglobin	(g/dL)	
Full	data	set	
11.13		
(10.69,	11.58)	
0.003		
(-0.004,	0.01)	
0.425	
Haemoglobin	(g/dL)	
Restricted	data	set	
10.32	(9.48,	11.17)	 0.006	(-0.008,	0.020)	 0.386	
White	cells	(x	10
9
/L)
	
Full	data	set	only	
10.62		
(9.54,	11.70)	
-0.037		
(-0.196,	0.121)	
0.645	
Lymphocytes	(x	10
9
/L)	
Full	data	set	only	
0.92		
(0.79,	1.06)	
0.005		
(-0.010,	0.019)	
0.502	
Sodium	(mmol/L)	
Full	data	set	only	
138.6		
(137.0,	140.3)	
-0.257		
(-0.441,	-0.072)	
0.006	
Potassium	(mmol/L)	
Full	data	set	only	
4.5		
(4.3,	4.7)	
-0.014		
(-0.036,	0.008)	
0.205	
Urea	(mmol/L)	
Full	data	set	only	
22.5	
(19.2,	25.8)	
-0.562		
(-0.871,	-0.254)	
<0.001	
Creatinine		(µmol/L)	
Full	data	set	only	
198.9		
(171.1,	226.6)	
-3.191		
(-5.413,	-0.970)	
0.005	
	
